Anti-PD-1-directed checkpoint inhibitors (pembrolizumab and nivolumab) are monoclonal antibodies against the surface receptor programmed cell death-1 (PD-1), approved for treatment of metastatic melanoma. The gene discussed is PDCD1; the disease is metastatic melanoma.